Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075167 | 0.84 | ABL1 (0.47) | ARMEN1GAAMAPTKMT2A | |
| SCHEMBL4084485 | 0.83 | NPC1 (0.41) | ARMEN1GAAMAPTKMT2A | |
| SCHEMBL4078988 | 0.83 | GAA (0.55) | ARSIRT5MEN1GAAMAPT | |
| SCHEMBL4089532 | 0.82 | ABL1 (0.47) | ARMEN1GAAMAPTKMT2A | |
| SCHEMBL4076674 | 0.81 | MAPT (0.52) | ARMEN1GAAMAPTKMT2A | |
| SCHEMBL3167605 | 0.81 | SIRT5 (0.45) | ARSIRT5MEN1GAAMAPT | |
| SCHEMBL4075290 | 0.81 | PGR (0.40) | ARMEN1GAAMAPTRECQL | |
| SCHEMBL4075016 | 0.80 | AR (0.43) | CYP11B2CYP11B1KDM1AARSIRT5 | |
| SCHEMBL4075018 | 0.79 | SMN1; SMN2 (0.51) | ARSIRT5MEN1MAPTKMT2A | |
| SCHEMBL4073551 | 0.78 | AR (0.54) | ARMEN1GAAMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501031-B | Oxazolidone derivatives as PR modulators | WYETH (US) | 2012-02-01 | — | — | CN | claimed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | claimed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | claimed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | claimed |
| CN-101501031-B | Oxazolidone derivatives as PR modulators | WYETH (US) | 2012-02-01 | — | — | CN | disclosed |
| US-7652018-B2 | Imidazolidin-2-one derivatives useful as PR modulators | WYETH LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-7618989-B2 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| CN-101501031-A | Oxazolidone derivatives as pr modulators | WYETH CORP (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008021339-A2 | PYRROLIDINE AND RELATED DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021338-A2 | TRICYCLIC OXAZOLIDONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021309-A1 | IMIDAZOLIDIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | PKD1, SHBG, NPY4R | CYP11B2 2013/4885CYP11B1 1692/4885KDM1A 222/4885 |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | PRLHR, GNRHR, NPY1R | CYP11B2 866/4885CYP11B1 843/4885KDM1A 369/4885 |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | MC2R, GNRHR, MC3R | CYP11B2 844/4885CYP11B1 1004/4885KDM1A 1314/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | CYP11B2 945/4885CYP11B1 1116/4885KDM1A 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.